{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:05:45Z","timestamp":1767927945474,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"DOI":"10.7759\/cureus.47006","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T05:22:41Z","timestamp":1697260961000},"source":"Crossref","is-referenced-by-count":8,"title":["The Current Advancement in Psoriasis"],"prefix":"10.7759","author":[{"given":"Aishwarya P","family":"Bhagwat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhushan","family":"Madke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:1475. 10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184347","article-title":"Risk factors for the development of psoriasis","volume":"20","author":"Kamiya K","year":"2019","unstructured":"Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019, 20:4347. 10.3390\/ijms20184347","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031448","article-title":"Cohort profile: the clinical \u2018Psoriasis in Adolescents\u2019 (PIA) cohort in Denmark","volume":"9","author":"Blegvad C","year":"2019","unstructured":"Blegvad C, Andersen AM, Groot J, Zachariae C, Skov L. Cohort profile: the clinical \u2018Psoriasis in Adolescents\u2019 (PIA) cohort in Denmark. BMJ Open. 2019, 9:e031448. 10.1136\/bmjopen-2019-031448","journal-title":"BMJ Open"},{"key":"ref4","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n F","year":"2020","unstructured":"Gr\u00e4n F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current developments in the immunology of psoriasis. Yale J Biol Med. 2020, 93:97-110.","journal-title":"Yale J Biol Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3384","article-title":"Psoriasis and genetics","volume":"100","author":"Dand N","year":"2020","unstructured":"Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and genetics. Acta Derm Venereol. 2020, 100:54-64. 10.2340\/00015555-3384","journal-title":"Acta Derm Venereol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1978.01640180008002","article-title":"Psoriasis in an unselected series of twins","volume":"114","author":"Brandrup F","year":"1978","unstructured":"Brandrup F, Hauge M, Henningsen K, Eriksen B. Psoriasis in an unselected series of twins. Arch Dermatol. 1978, 114:874-8. 10.1001\/archderm.1978.01640180008002","journal-title":"Arch Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.010","article-title":"The genetic basis of psoriasis","volume":"25","author":"Valdimarsson H","year":"2007","unstructured":"Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol. 2007, 25:563-7. 10.1016\/j.clindermatol.2007.08.010","journal-title":"Clin Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa K","year":"2020","unstructured":"Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020, 99:2-8. 10.1016\/j.jdermsci.2020.05.008","journal-title":"J Dermatol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312793","article-title":"The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications","volume":"22","author":"Singh R","year":"2021","unstructured":"Singh R, Koppu S, Perche PO, Feldman SR. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021, 22:12793. 10.3390\/ijms222312793","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.01.006","article-title":"Nail psoriasis","volume":"113","author":"Canal-Garc\u00eda E","year":"2022","unstructured":"Canal-Garc\u00eda E, Bosch-Amate X, Belinch\u00f3n I, Puig L. Nail psoriasis. Actas Dermosifiliogr. 2022, 113:481-90. 10.1016\/j.ad.2022.01.006","journal-title":"Actas Dermosifiliogr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3388","article-title":"Pustular psoriasis: the dawn of a new era","volume":"100","author":"Bachelez H","year":"2020","unstructured":"Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020, 100:87-92. 10.2340\/00015555-3388","journal-title":"Acta Derm Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2021.05.011","article-title":"Generalized pustular psoriasis (von Zumbusch)","volume":"97","author":"Romiti R","year":"2022","unstructured":"Romiti R, Hirayama AL, Arnone M, Magalh\u00e3es RF. Generalized pustular psoriasis (von Zumbusch). An Bras Dermatol. 2022, 97:63-74. 10.1016\/j.abd.2021.05.011","journal-title":"An Bras Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00655-y","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"23","author":"Marrakchi S","year":"2022","unstructured":"Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022, 23:13-9. 10.1007\/s40257-021-00655-y","journal-title":"Am J Clin Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22169048","article-title":"Generalised pustular psoriasis: divergence of innate and adaptive immunity","volume":"22","author":"Samotij D","year":"2021","unstructured":"Samotij D, Szcz\u0119ch J, Reich A. Generalised pustular psoriasis: divergence of innate and adaptive immunity. Int J Mol Sci. 2021, 22:9048. 10.3390\/ijms22169048","journal-title":"Int J Mol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00658-9","article-title":"Treatment options and goals for patients with generalized pustular psoriasis","volume":"23","author":"Krueger J","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022, 23:51-64. 10.1007\/s40257-021-00658-9","journal-title":"Am J Clin Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00612-x","article-title":"Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options","volume":"11","author":"Menter A","year":"2021","unstructured":"Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021, 11:1917-29. 10.1007\/s13555-021-00612-x","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso AM","year":"2021","unstructured":"Brunasso AM, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021, 10:62. 10.12703\/r\/10-62","journal-title":"Fac Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","article-title":"Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database","volume":"5","author":"Kubota K","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, Nakagawa H. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015, 5:e006450. 10.1136\/bmjopen-2014-006450","journal-title":"BMJ Open"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12899","article-title":"Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature","volume":"32","author":"Galluzzo M","year":"2019","unstructured":"Galluzzo M, D'Adamio S, Teoli M, Bianchi L, Talamonti M. Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019, 32:e12899. 10.1111\/dth.12899","journal-title":"Dermatol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo D V","year":"2019","unstructured":"Ocampo D V, Gladman D. Psoriatic arthritis. F1000Res. 2019, 8:1665. 10.12688\/f1000research.19144.1","journal-title":"F1000Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/x3sfxe","article-title":"Psoriatic arthritis: one year in review 2022","volume":"40","author":"Cigolini C","year":"2022","unstructured":"Cigolini C, Fattorini F, Gentileschi S, Terenzi R, Carli L. Psoriatic arthritis: one year in review 2022. Clin Exp Rheumatol. 2022, 40:1611-9. 10.55563\/clinexprheumatol\/x3sfxe","journal-title":"Clin Exp Rheumatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01039-1","article-title":"Enthesitis in psoriatic arthritis, the sonographic perspective","volume":"23","author":"Smerilli G","year":"2021","unstructured":"Smerilli G, Di Matteo A, Cipolletta E, Grassi W, Filippucci E. Enthesitis in psoriatic arthritis, the sonographic perspective. Curr Rheumatol Rep. 2021, 23:75. 10.1007\/s11926-021-01039-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221086710","article-title":"Psoriatic arthritis: prospects for the future","volume":"14","author":"Hackett S","year":"2022","unstructured":"Hackett S, Ogdie A, Coates LC. Psoriatic arthritis: prospects for the future. Ther Adv Musculoskelet Dis. 2022, 14:1759720X221086710. 10.1177\/1759720X221086710","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid C","year":"2020","unstructured":"Reid C, Griffiths CE. Psoriasis and treatment: past, present and future aspects. Acta Derm Venereol. 2020, 100:69-79. 10.2340\/00015555-3386","journal-title":"Acta Derm Venereol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2147\/btt.s2116","article-title":"Infliximab for the treatment of plaque psoriasis","volume":"2","author":"Gall JS","year":"2008","unstructured":"Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008, 2:115-24. 10.2147\/btt.s2116","journal-title":"Biologics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s1265","article-title":"Treating psoriasis with adalimumab","volume":"4","author":"Alwawi EA","year":"2008","unstructured":"Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008, 4:345-51. 10.2147\/tcrm.s1265","journal-title":"Ther Clin Risk Manag"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.4.1464839","article-title":"Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials","volume":"46","author":"Farhi D","year":"2010","unstructured":"Farhi D. Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. Drugs Today (Barc). 2010, 46:259-64. 10.1358\/dot.2010.46.4.1464839","journal-title":"Drugs Today (Barc)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212594","article-title":"Guselkumab for the treatment of psoriasis - evidence to date","volume":"8","author":"Nogueira M","year":"2019","unstructured":"Nogueira M, Torres T. Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context. 2019, 8:212594. 10.7573\/dic.212594","journal-title":"Drugs Context"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1624","article-title":"Meta-analyses of clinical efficacy of risankizumab and adalimumab in chronic plaque psoriasis: supporting evidence of risankizumab superiority","volume":"107","author":"Witjes H","year":"2020","unstructured":"Witjes H, Khatri A, Diderichsen PM, Mandema J, Othman AA. Meta-analyses of clinical efficacy of risankizumab and adalimumab in chronic plaque psoriasis: supporting evidence of risankizumab superiority. Clin Pharmacol Ther. 2020, 107:435-42. 10.1002\/cpt.1624","journal-title":"Clin Pharmacol Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2018.075","article-title":"Tildrakizumab for psoriasis","volume":"42","author":"Australian Prescriber","year":"2019","unstructured":"Australian Prescriber. Tildrakizumab for psoriasis. Aust Prescr. 2019, 42:40-1. 10.18773\/austprescr.2018.075","journal-title":"Aust Prescr"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621956","article-title":"Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies","volume":"12","author":"Bugaut H","year":"2021","unstructured":"Bugaut H, Aractingi S. Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol. 2021, 12:621956. 10.3389\/fimmu.2021.621956","journal-title":"Front Immunol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: a review in moderate to severe pediatric plaque psoriasis","volume":"23","author":"Blair HA","year":"2021","unstructured":"Blair HA. Secukinumab: a review in moderate to severe pediatric plaque psoriasis. Paediatr Drugs. 2021, 23:601-8. 10.1007\/s40272-021-00476-w","journal-title":"Paediatr Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00548-2","article-title":"Dynamic visual representation of clinical efficacy of ixekizumab in psoriasis","volume":"11","author":"Hawkes JE","year":"2021","unstructured":"Hawkes JE, See K, Burge R, et al.. Dynamic visual representation of clinical efficacy of ixekizumab in psoriasis. Dermatol Ther (Heidelb). 2021, 11:1107-18. 10.1007\/s13555-021-00548-2","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes AC","year":"2019","unstructured":"Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019, 8:212570. 10.7573\/dic.212570","journal-title":"Drugs Context"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions","volume":"156","author":"Sachen KL","year":"2022","unstructured":"Sachen KL, Arnold Greving CN, Towne JE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022, 156:155897. 10.1016\/j.cyto.2022.155897","journal-title":"Cytokine"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair HA","year":"2022","unstructured":"Blair HA. Spesolimab: first approval. Drugs. 2022, 82:1681-6. 10.1007\/s40265-022-01801-4","journal-title":"Drugs"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis","volume":"81","author":"P\u00e9rez-Jeldres T","year":"2021","unstructured":"P\u00e9rez-Jeldres T, Alvarez-Lobos M, Rivera-Nieves J. Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis. Drugs. 2021, 81:985-1002. 10.1007\/s40265-021-01528-8","journal-title":"Drugs"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama M","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020, 21:7488. 10.3390\/ijms21207488","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov A","year":"2014","unstructured":"Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al.. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014, 111:16814-9. 10.1073\/pnas.1414189111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent","volume":"84","author":"Bissonnette R","year":"2021","unstructured":"Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021, 84:1059-67. 10.1016\/j.jaad.2020.10.085","journal-title":"J Am Acad Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15931","article-title":"Tapinarof for the treatment of psoriasis","volume":"35","author":"Nogueira S","year":"2022","unstructured":"Nogueira S, Rodrigues MA, Vender R, Torres T. Tapinarof for the treatment of psoriasis. Dermatol Ther. 2022, 35:e15931. 10.1111\/dth.15931","journal-title":"Dermatol Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic jak inhibitors in dermatology","volume":"10","author":"Solimani F","year":"2019","unstructured":"Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic jak inhibitors in dermatology. Front Immunol. 2019, 10:2847. 10.3389\/fimmu.2019.02847","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20132090","article-title":"Obesity and dyslipidemia in patients with psoriasis treated at a dermatologic clinic in Manaus","volume":"88","author":"Santos M","year":"2013","unstructured":"Santos M, Fonseca HM, Jalkh AP, Gomes GP, Cavalcante Ade S. Obesity and dyslipidemia in patients with psoriasis treated at a dermatologic clinic in Manaus. An Bras Dermatol. 2013, 88:913-6. 10.1590\/abd1806-4841.20132090","journal-title":"An Bras Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1079","article-title":"Psoriasis is associated with lipid abnormalities at the onset of skin disease","volume":"54","author":"Mallbris L","year":"2006","unstructured":"Mallbris L, Granath F, Hamsten A, St\u00e5hle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006, 54:614-21. 10.1016\/j.jaad.2005.11.1079","journal-title":"J Am Acad Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102211","article-title":"Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment","volume":"18","author":"Hu SC","year":"2017","unstructured":"Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017, 18:2211. 10.3390\/ijms18102211","journal-title":"Int J Mol Sci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino L","year":"2022","unstructured":"Mastorino L, Dapavo P, Avallone G, et al.. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?. J Dermatolog Treat. 2022, 33:2495-502. 10.1080\/09546634.2021.1970706","journal-title":"J Dermatolog Treat"},{"key":"ref47","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.06.057","article-title":"Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents","volume":"80","author":"Kaushik SB","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019, 80:27-40.","journal-title":"J Am Acad Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand JM","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006, 296:1735-41. 10.1001\/jama.296.14.1735","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.15.1670","article-title":"Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' Health Study II","volume":"167","author":"Setty AR","year":"2007","unstructured":"Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' Health Study II. Arch Intern Med. 2007, 167:1670-5. 10.1001\/archinte.167.15.1670","journal-title":"Arch Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand JM","year":"2009","unstructured":"Gelfand JM, Dommasch ED, Shin DB, Azfar RS, Kurd SK, Wang X, Troxel AB. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009, 129:2411-8. 10.1038\/jid.2009.112","journal-title":"J Invest Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan SM","year":"2012","unstructured":"Langan SM, Seminara NM, Shin DB, et al.. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012, 132:556-62. 10.1038\/jid.2011.365","journal-title":"J Invest Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184761-the-current-advancement-in-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:23Z","timestamp":1707509183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184761-the-current-advancement-in-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.47006","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}